Skip to main content
. 2016 Jan 26;86(4):375–381. doi: 10.1212/WNL.0000000000002314

Figure 3. %CD62L is not a reliable biomarker for progressive multifocal leukoencephalopathy (PML) risk stratification.

Figure 3

For each patient in the STRATA cohort who developed PML, matched control samples were also stained for %CD62L. Patients with PML at diagnosis (red circles) and their preceding pre-PML longitudinal time points (black circles) are plotted along with matched controls (open circles) on individual plots.